'Pd l1' presentation slideshows

GI SLIDE DECK 2019 Selected abstracts from:

GI SLIDE DECK 2019 Selected abstracts from:. Letter from ESDO. DEAR COLLEAGUES

847 views • 84 slides

Program Goals

Program Goals. Introduction. Using Vaccines in the Treatment of NSCLC. Vaccine Approach in NSCLC Targeting Tumor Antigens. Vaccines Evaluated in Phase 3 Lung Cancer Trials Study Designs. Vaccines Evaluated in Phase 3 Lung Cancer Trials (cont) Study Designs.

715 views • 60 slides

This event will take place at the AATS International Thoracic Surgical Oncology Summit.

The Evolving Role of Immunotherapy as a Component of Multimodal Therapy in Earlier Stages of Lung Cancer Rationale, Current Evidence, Key Trials, and Implications for Multidisciplinary Care. This event will take place at the AATS International Thoracic Surgical Oncology Summit. Disclosures.

593 views • 59 slides

October 26 th , 2018

481 views • 47 slides

Expert Perspectives on Immunotherapy for NSCLC: Practical Guidance and Recommendations

Expert Perspectives on Immunotherapy for NSCLC: Practical Guidance and Recommendations. This program is supported by an educational grant from Merck and Co., Inc. About These Slides.

767 views • 46 slides

Evolving Therapeutic Strategies in Triple Negative Breast Cancer: SABCS 2018 Hope S. Rugo, MD

Evolving Therapeutic Strategies in Triple Negative Breast Cancer: SABCS 2018 Hope S. Rugo, MD Professor of Medicine Director, Breast Oncology and Clinical Trials Education University of California San Francisco Comprehensive Cancer Center San Francisco, CA USA. Topics. Immunotherapy

668 views • 38 slides

Tumor Mutation Burder as a predictive biomarker

Tumor Mutation Burder as a predictive biomarker. Dr Francesco Pantano, MD PhD Medical Oncology Department Campus Bio Medico of Rome. Relevance of TMB in immunotherapy-treated patients. TMB is a surrogate of neo-antigen load

475 views • 31 slides

Resultados de sobrevida a largo plazo en CheckMate 057 y CheckMate 017

286 views • 28 slides

ASCO G.U. 2014 Lawrence H. Einhorn

522 views • 25 slides

Difficulties with network meta-analysis when starting to use PD-L1 thresholds

Difficulties with network meta-analysis when starting to use PD-L1 thresholds. Disclaimer. The views and opinions expressed in the following PowerPoint slides are those of the individual presenter and should not be attributed to AstraZeneca. Summary presentation.

237 views • 22 slides

Disclosures

Phase Ib Study Results: Subgroup Efficacy Analysis of Atezolizumab + Bevacizumab in Patients With Previously Untreated, Unresectable Hepatocellular Carcinoma.

171 views • 15 slides

About These Slides

Phase II KEYNOTE-170/KEYNOTE-013 Update: Pembrolizumab in Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma. Integrating New Malignant Hematology Findings Into Practice: Independent Conference Coverage of ASH 2018* December 1-4, 2018; San Diego, California.

253 views • 10 slides

Gianni L et al. Proc SABCS 2012 ; Abstract GS6-7.

Adaptive Immune System and Immune Checkpoints Are Associated with Response to Pertuzumab (P) and Trastuzumab (H) in the NeoSphere Study. Gianni L et al. Proc SABCS 2012 ; Abstract GS6-7. Background.

238 views • 9 slides

Commercial Aspects of PD-1 and PD-L1 Inhibitors Market 2016

The report provides an update on the recent collaborations occurring in the PD-1 and PDL-1 market and the companies looking for partnership for the same. Report also covers Commercial Aspects such as the Current and Future Market, Barriers and challenges and SWOT analysis. Get Sample Broucher of the Report @ http://www.marketintelreports.com/pdfdownload.php?id=DRSR2016002

164 views • 6 slides

IVD Antibody Development Services for PD-L1 Marker

As an undisputed world-leading service provider and research institution, Creative Biolabs is professional in discovery and development of in vitro diagnostics (IVD) antibodies. Based on years of experience, vast expertise and advanced platform, we could offer world-class IVD antibody libraries with the best quality and highly specificity.

34 views • 3 slides

Assessing The Role of PD-L1 in Tumor Microenvironment and Tumor Progression in Vivo

https://www.creative-biogene.com/blog/index.php/2018/07/29/assessing-the-role-of-pd-l1-in-tumor-microenvironment-and-tumor-progression-in-vivo/

27 views • 2 slides

https://www.creative-biogene.com/blog/index.php/2018/07/29/inhibition-of-the-secretion-of-tumor-exosomes-pd-l1-may-become-an-important-anti-cancer-target-md-anderson-report/

22 views • 2 slides

Research status of PD-1 and PD-L1

28 views • 2 slides

PD-1/PDL-1 Signaling Pathway

Programmed cell death protein 1, also known as PD-1 and CD279, is a cell surface receptor that plays an important role in down-regulating the immune system and promoting self-tolerance by suppressing T cell inflammatory activity. In humans, it is encoded by the PDCD1 gene. PD-1 is a member of the immunoglobulin superfamily and is expressed on T-cells and pro-B cells.

26 views • 1 slides